# EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy

> **NCT00391534** · PHASE3 · TERMINATED · sponsor: **Desitin Arzneimittel GmbH** · enrollment: 100 (estimated)

## Conditions studied

- Partial Epilepsy

## Interventions

- **DRUG:** modified release formulation of oxcarbazepine (OXC MR)
- **DRUG:** immediate release formulation of oxcarbazepine (OXC IR)

## Key facts

- **NCT ID:** NCT00391534
- **Lead sponsor:** Desitin Arzneimittel GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-10
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 100 (ESTIMATED)
- **Why stopped:** Low recruitment rate
- **Last updated:** 2010-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00391534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00391534, "EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00391534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*